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Abstract
Introduction: Myofascial pain dysfunction syndrome (MPDS) is a common temporomandibular 
joint disorder. Due to its multifactorial etiology, treatment usually involves more than one modality 
to obtain complementary results. The purpose of this study was to compare the combined 
effect of a low-level laser, a hard occlusal appliance, and conventional pharmacotherapy with 
pharmacotherapy only in the management of patients with MPDS.
Methods: In this study, 15 patients with MPDS were diagnosed and randomly assigned to 3 groups 
(n=5). Subjects in Group 1 were treated with pharmacotherapy (PT); Group 2 received the diode 
laser (940 nm gallium arsenide) every other day for a total of 10 sessions, plus pharmacotherapy 
(PTL) and Group 3 were given hard occlusal splint 12 h/day for 4 weeks, plus pharmacotherapy 
(PTO). The intensity of pain was measured using the visual analog scale (VAS) prior to the treatment, 
2 and 4 weeks after the onset of treatment and 2 weeks later. The maximum painless mouth opening 
and pain intensity at muscle palpation were also recorded. Comparisons were made between the 
groups via repeated measure analysis of variance (ANOVA) (P < 0.05).
Results: Pain relief in the subjective VAS was observed in both laser and appliance groups in the 
third and fourth examination sessions (P < 0.05). No statistically significant reduction in pain was 
noted using pharmacotherapy only. The maximum painless mouth opening and muscle tenderness 
were not significantly different between the 3 groups (P > 0.05).
Conclusion: Both the laser and the occlusal appliance combined with pharmacotherapy proved 
to be effective for pain reduction in patients with MPDS. All groups, however, failed to result in a 
significant improvement in the maximum mouth opening or tenderness in masticatory muscles.
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Introduction
Temporomandibular disorders (TMDs) are the major 
etiology of non-dental pain in the orofacial region,1 with a 
prevalence of 40 to 60% in the community, involving more 
frequently women than men.2 One of the most common 
types of TMDs is the myofascial pain dysfunction 
syndrome (MPDS), characterized by pain and tenderness 
in one or more of the masticatory muscles during 
functional activities of the jaw and frequently associated 
with a limitation in the mouth opening.3 Even though 
the condition is considered one of the most common 
causes of chronic pain in the orofacial region, it is not well 
understood.4-6 Psychological disorders, especially distress 
and anxiety and occlusal interferences have shown to play 
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a part in its etiology.7
Due to the rather unclear etiopathogenesis and the 
multifactorial origin of MPDS, clinicians mostly propose 
a multidisciplinary approach to manage the condition, 
including physical as well as psychological therapy.8 
Conservative physical therapy plays a prominent role 
in the treatment of TMDs through a wide range of 
techniques, including manual therapy (for example, 
joint mobilization/manipulations and soft-tissue 
mobilization), therapeutic exercise, electrotherapy (for 
example, low-level laser therapy (LLLT), transcutaneous 
electrical nerve stimulation, therapeutic ultrasound, and 
shortwave), dry needling, and acupuncture.8,9 Other 
modalities include pharmaceutical therapy, occlusal 
splints, and biofeedback.10-17
Since pain is typically the reason for the patients with 
TMDs to seek medical care, pharmacological therapy 
is most often indicated as the first line of treatment.10 
A wide variety of drugs ranging from short-term 
treatment with non-steroidal anti-inflammatory drugs 
and muscle relaxants to the long-term administration 
of antidepressants for less well-characterized pain have 
been used.10,11 Although several medications are typically 
prescribed, many lack evidence for this specific pathology 
and are rather empirical.12
Occlusal splint therapy is chosen for the treatment of 
pain and dysfunction in the orofacial region for several 
reasons. It is relatively simple, noninvasive and reversible. 
Moreover, a high degree of patients’ acceptance has been 
reported, especially with the soft splints.13,14
LLLT has recently been put under the spotlight because 
it’s safe, non-invasive, easy to use, fast, and aseptic and has 
few contraindications.15 It is almost well tolerated at any age. 
The basic effects of LLLT are biostimulative, regenerative, 
analgesic, and anti-inflammatory.16 In a randomized 
clinical trial, LLLT for the treatment of patients with a 
myogenous temporomandibular joint disorder produced 
a significant improvement in the pain level and mouth 
opening.17 Lasers in conjunction with pharmaceutical 
therapy for Trigeminal Neuralgia were shown to be 
effective in reducing the dosage of pharmacotherapy 
and hence their side effects.18 Literature reviews  usually 
indicate that LLLT is effective in reducing pain in TMDs 
mostly through its anti-inflammatory effects.15,16,19 
However, a systematic review in 2012 concluded no 
definitive results could be drawn on the efficacy of LLLT 
in the treatment of TMDs except that it was probably 
more effective in the treatment of TMJ disorders and less 
effective in masticatory muscle disorders.20 Therefore, 
the relative clinical efficacy of LLLT in the treatment of 
TMD is controversial and sufficient evidence is lacking 
regarding its benefits in MPDS.21 Beside the widely 
variable parameters, comparisons have often been made 
between traditional pharmacotherapy and new treatment 
modalities such as the laser, rather than combined effects. 
It is believed that combining various types of treatments 
in TMDs could result in not only a better treatment 
outcome but also a reduction in the dosage and duration 
of pharmacotherapy and therefore their side effects.8,9,15 
The purpose of this study was to compare the efficacy of 
pharmaceutical therapy only with its use in combination 
with the laser and the occlusal appliance in the treatment 
of MPDS. 
Materials and Methods 
In this study, the cases were selected from the patients 
referring to the Pain Department of Tehran University of 
Medical Sciences, Dental School, International Campus 
from October to December 2016. Our patients were 
selected according to the standardized examination/
diagnosis procedure based upon the Research Diagnostic 
Criteria for Temporomandibular Disorders (RDC/
TDM).1
The inclusion criteria were age between 18 to 65 years, 
no history of orthodontic treatment and the presence of 
all teeth in the oral cavity.22 Admission criteria included a 
diagnosis of MPDS based on at least two of the following23:
• Pain during mastication and functional and 
parafunctional movements.
• Pain in the ear, jaw, preauricular area and the 
temporal region 
• A complaint of pain at the site of either masseter 
temporalis, medial pterygoid or lateral pterygoid 
muscles 
• A complaint of pain during the mouth opening or at 
the maximum mouth opening 
The exclusion criteria were pregnancy, history of 
pharmacotherapy for MPDS in the past two weeks and 
any kind of systemic diseases.22
Fifteen patients with MPDS (n = 5) participated in this 
preliminary study. The purpose of the study was described 
to each participant and informed consent was obtained 
prior to the onset of the treatment. These patients were 
interviewed and evaluated by an oral medicine specialist. 
Their medical history and a panoramic radiograph were 
taken to rule out disorders from dental and joint origins 
and then their related data were registered. In the first 
examination session, the pain level and jaw movements 
were recorded. The primary examination included 
locating the exact site of pain, the assessment of pain 
severity, and the tenderness of the muscles of mastication 
(masseter, temporalis, medial and lateral pterygoid) 
using the visual analog scale (VAS). The VAS ranged 
from 0-10; 10 indicated the most severe pain imaginable, 
while 0 indicated no pain. The maximum painless mouth 
opening was also measured using a ruler. All patients 
received necessary instructions for home care, quitting 
parafunctional habits, behavioral therapy, and relaxation 
exercises, and examinations were repeated 2 weeks after. 
The patients were then divided into 3 groups using block 
randomization for intervention. The treatment in all 
groups started at the same time and was performed by an 
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oral medicine specialist. For the third group, the entire 
clinical procedure for occlusal appliance therapy was 
performed by a prosthodontist and the laboratory works 
were done by an expert prosthetic technician. 
 
Group 1: Pharmacotherapy
The patients in this group received muscle relaxant, 500 
mg methocarbamol (Amin Chemical & Pharmaceutical 
Co., Tehran, Iran) 3 times a day, a non-steroidal anti-
inflammatory drug, 250 mg naproxen (Pars Darou Co., 
Tehran, Iran) twice a day, and benzodiazepine, 1 mg 
(one-fourth of a tablet) clonazepam (Sobhan Darou Co., 
Tehran, Iran) once a day for a period of 2 weeks.10-12,23 
Group 2: Low-level Diode Laser Along With Pharmacotherapy 
The patients in this group received pharmacotherapy and 
also underwent laser irradiation. Pharmacotherapy was 
prescribed in the same way as the first group. Laser therapy 
was performed using the low-level gallium arsenide diode 
laser (Biolase, USA) at a 940 nm wavelength with 0.2 W 
output power and 2 J energy. 
Laser calibration was done before use and the laser 
probe was disinfected with alcohol before each treatment. 
The laser in a non-contact mode was irradiated on the 
involved muscle for 10 seconds with an energy density 
of 2.5 J/cm2 (ED = 10/0.785× 0.2 cm2 =2/0.8 =2.5 J/cm2). 
Treatment sessions were scheduled 3 days a week (every 
other day) for a total of 10 sessions.12 The probe was held 
perpendicular to the targeted muscle. The masticatory 
muscles were evaluated bilaterally with firm and constant 
pressure to define painful areas. For each painful 
masticatory muscle, the laser light was delivered to the 
tender points diagnosed at the start of the treatment.
Group 3: Occlusal appliance plus pharmacotherapy 
The patients in this group received both pharmacotherapy 
and the occlusal appliance. Pharmacotherapy was 
performed in the same way as the first group. For the 
fabrication of occlusal appliances, a full arch alginate 
impression (Zhermack, Germany) free of bubbles and 
voids was taken from both jaws using prefabricated stock 
trays. Centric relation was recorded via silicone bite 
registration paste (Futar D, Kettenbach GmbH & Co., 
Germany) and the impressions were poured immediately. 
A stone cast was then obtained in less than 20 minutes, 
trimmed to the depth of a vestibule and mounted on a 
semi-adjustable articulator (Mani, Tehran, Iran). For 
all the patients, a hard maxillary occlusal appliance was 
fabricated. Undercuts in the maxillary arch were blocked 
out, and the appliance developed in wax. The waxed 
appliance was then invested and processed with heat-
cured acrylic resin (Acropars, Iran). Final adjustments 
for fit and contacts were made intraorally.21 The occlusal 
appliances were delivered to the patients and they were 
instructed to use them for a minimum of 8 hours a day 
for 1 month. 
Parameters were measured prior to the treatment, 2 
and 4 weeks after the onset of the treatment and 2 weeks 
later. The efficacy of the treatment in terms of change 
in the severity of pain was assessed using the VAS. The 
maximum painless mouth opening was also measured as 
the functional index. 
The functional examination was based on RDC/TDM, 
and pressure pain values were obtained with the VAS. The 
data were analyzed using SPSS version 25. The qualitative 
variables among the groups were compared using the 
repeated measures ANOVA (P < 0.05). As the interaction 
between the time of examination and study groups 
became significant, one-way ANOVA with a post hoc test 
(Dunnett’s T3) was used to compare the VAS at different 
examination time in each group. 
Results 
All participants completed the study. They included 
11 females and 4 males in the age range of 26-63 years, 
distributed randomly among the 3 groups. The mean 




No significant changes were noted in pain severity 
based on the VAS score in any groups between the first 
and second sessions. In the third and fourth sessions, 
the mean pain scores in the pharmacotherapy plus the 
laser group and the pharmacotherapy plus the occlusal 
appliance group were significantly lower than those 
in the pharmacotherapy only group. No significant 
differences in pain severity reduction were noted 
between the pharmacotherapy plus the laser group and 
the pharmacotherapy plus the occlusal appliance group 
(P > 0.05) (Table 2). 
Maximum Painless Mouth Opening
The mean maximum painless mouth opening in the first 
session was not significantly different among the study 
groups (Figure 1). Likewise, changes the in maximum 
mouth opening were not significant in any of the groups 
after the completion of treatment sessions. 
Muscle Tenderness
Four main masticatory muscles were examined for 
muscle tenderness: masseter, temporalis, medial, and 
lateral pterygoids. In the first session, the highest and 
lowest muscular involvement was noted in the masseter 
and temporalis respectively (Figure 2).
VAS score analysis revealed no changes in tenderness 
in any of the 4 muscles during the treatment sessions 
between the study groups (Figure 3). 
Discussion 
The effectiveness of pharmacotherapy only versus the 
combined LLLT and pharmacotherapy and the occlusal 
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appliance plus pharmacotherapy in the treatment of the 
patients with MPDS was investigated in this study, using 
the parameters of pain intensity, the maximum painless 
mouth opening, and muscle tenderness. 
Eleven females and 4 males who met our inclusion 
criteria participated in the study. The higher prevalence 
of females was actually in line with most epidemiologic 
studies around TMDs24,25 and is mostly attributed to 
hormonal and bio-behavioral factors, a higher demand 
for treatment among females, and their higher proneness 
to psychological disorders.26 The mean age of the patients 
in the study groups was 52, 56.40 and 40.80 respectively, 
confirming that it is primarily a condition of young and 
middle-aged adults rather than children or the elderly.27 
The highest prevalence of muscle involvement was 
noted in masseter and the lowest in temporalis. The same 
pattern of involvement was seen by Michelotti et al who 
assessed the additional value of a home physical therapy 
regimen versus patient education only for the treatment 
Table 1. Descriptive statistics of the Pain Score (VAS), Including Minimum, Maximum, Mean, and Standard Deviation Values of Different Study Groups at 
Different Examination Sessions
Study Group Examination Session Minimum Maximum Mean Standard Deviation
PTO
1 8 9 8.40 .548
2 4 8 5.00 1.732
3 2 4 2.60 .894
4 1 4 2.40 1.342
PTL
1 6 10 8.00 1.581
2 3 7 5.40 1.517
3 3 5 4.20 1.095
4 2 6 3.80 1.483
PT
1 6 10 8.00 1.581
2 5 8 6.00 1.225
3 4 7 5.20 1.095
4 4 7 5.20 1.095
Note: PTO, Pharmacotherapy +occlusal appliance; PTL, pharmacotherapy + Laser; PT, Pharmacotherapy only.
Table 2. The Comparison of the Pain Score Between the 3 Groups at Different 
Sessions

















Note: PTO, Pharmacotherapy +occlusal appliance; PTL, pharmacotherapy 
+ Laser; PT, Pharmacotherapy only.
P value = 0.05, confidence interval=95%.
Figure 1. The Error Bar of the Mean Maximum Painless Mouth Opening 
and 95% Confidence Interval in the Study Groups.






























Masseter Temporal Lateral petrygoid Medial petrygoid
of myofascial pain of the jaw muscles.28 Kato et al29 and Oz 
et al,30 assessing the efficacy of LLLT in the management 
of TMDs, reported the involvement of masseter and 
temporalis in all patients. In a study by Fouda et al, 
masseter and temporalis were the most commonly 
involved muscles.31 In the studies by Mortazavi et al32 and 
Darbandi et al,33 investigating TMJ disorders and MPDS, 
medial pterygoid was observed to be the most commonly 
involved muscle.
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The use of the low-level laser has been suggested for 
the treatment of different myofascial and skeletal pain 
syndromes such as MPDS due to its anti-inflammatory 
and analgesic properties. It decreases muscle tension and 
regulates cellular activities.24,26,34,35 In our study, the laser 
at a 940 nm wavelength was irradiated and it resulted 
in a significant reduction in pain in all the patients. 
The positive outcome of LLLT was demonstrated in 
previous studies by Salmos-Brito et al,36 Ahrari et al,17 
Mazzetto et al,37 Shirani et al,38 Ebrahimi et al,18 Azizi 
et al,22 and Khalighi et al,39 who all found a significant 
reduction in pain intensity of TMD patients with LLLT. 
Khalighi et al assessed the efficacy of 810 nm gallium-
aluminum-arsenide diode source laser therapy versus 
pharmacotherapy in improving MPDS in 40 patients. The 
patients in the laser group received a placebo drug and the 
patients in the naproxen group received a placebo laser. 
The maximum mouth opening also increased significantly 
in the laser group from the eighth session compared to 
those receiving 500 mg of naproxen.39 Our study, however, 
failed to demonstrate any significant improvement in 
the mean maximum painless mouth opening between 
the study groups. That might somehow be attributed to 
the differences in laser parameters, treatment sessions, 
and a longer follow-up period which was 2 months 
after completing the treatment in their study and only 2 
weeks in ours. Perhaps if we had continued to monitor 
the patients, we could have noticed pain reduction in 
their maximum painless mouth opening as well. Öz et 
al compared the efficacy of LLLT and the occlusal splint 
in patients with MPDS and reported similar results to 
ours. Pain and muscle tenderness were reduced, and the 
maximum mouth opening improved in both groups of 
the laser and the splint with no superiority between the 
two groups.30
The findings of this study are in contrast to Emshoff 
et al21 and da Cunha et al,40 who reported a significant 
reduction in pain intensity in both laser and placebo 
groups, suggesting that improvement was mostly due to 
the placebo effect of laser administration. However, the 
two studies focused on the efficacy of treatment in TMJ 
pain during function, and not MPDS.21,40 Our results were 
also in contrast to Katsoulis et al who reported a superior 
efficacy in the placebo group; however, they used the 
laser with a lower wavelength compared with our study 
(690 nm).41 Altan et al performed a study over 53 patients 
with cervical myofascial pain syndrome to investigate 
the effect of GaAs laser therapy. They used a frequency 
of 1000 Hz for 2 minutes over each trigger points in 
trapezius muscle bilaterally once a day for 10 days during 
a period of 2 weeks and failed to show the superiority 
of the tested modality. However, using the same laser at 
a 940 nm wavelength for 10 seconds, we encountered a 
great improvement in the laser plus pharmacotherapy 
group compared to pharmacotherapy only. The difference 
in results may come from differences in laser parameters 
including wavelength, frequency, output, and dosage as 
well as the number of subjects and the location of pain. 
Moreover, the control group in their study received no 
treatment except for the instructions on daily isometric 
exercises and stretching.42 
We recorded the pain level and jaw movements on the 
first visit. All the patients then received the necessary 
instructions for home care, quitting parafunctional 
habits, behavioral therapy, and relaxation exercises. 
Examinations were repeated 2 weeks after. The pain 
score (VAS) decreased not for more than 1 unit in all 
the patients, which indicated that the afore-mentioned 
initial treatments were not effective enough and other 
modalities were required.28 Since it was unethical to 
deprive the patients of the conventional treatment in 
one group to assess the efficacy of anther modality, 
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we designed the study with 3 groups and added laser 
therapy and the occlusal appliance to pharmacotherapy. 
Combined treatments are often used in a clinical setting. 
Lasers increase tissue resistance and the use of lasers and 
occlusal appliances decreases the need for taking too 
many medications and subsequently decreases the side 
effects of pharmacotherapy.42 
The use of the hard occlusal splint in this study caused a 
significant reduction in the mean pain score compared to 
pharmacotherapy only. Occlusal splint therapy is chosen 
for the treatment of pain and dysfunction in the orofacial 
region for several reasons. In a meta-analysis by Zhang, 
splints were reported to be effective for the treatment of 
TMJ disorders and its use was highly recommended.43 
Evaluating the clinical performance of different kinds of 
occlusal splints in the management of myofascial pain, 
Amin et al reported that soft, hard, and liquid oral splints 
all resulted in an optimal outcome at the end of 3 months; 
however, the hard splint proved to be more effective in 
a shorter period.44 Demirkol et al, in 2015, evaluated 
the efficacy of the occlusal splint and the low-level laser 
(Nd:YAG) in TMD patients characterized with myofascial 
pain versus the placebo. The control group received 
pharmaceutical therapy. They reported that both the 
occlusal splint and LLLT were effective in pain reduction, 
which was similar to our findings. Moreover, they showed 
that the laser was more effective than the occlusal splint 
in pain reduction.45
In this study, 250 mg naproxen, 500 mg methocarbamol, 
and 1 mg clonazepam were prescribed for all the patients 
over a period of 1 week. Naproxen should be administered 
every 12 hours for 10 to 14 days and patients might 
experience constipation, bloating, and stomachache.46 In 
a study by Guimaraes et al., naproxen was used in a gel 
form and no significant differences were noted between 
the naproxen and placebo groups.47 In the current study, 
we systemically prescribed naproxen in the tablets form, 
which is easier for use by the patients. The combination 
of drugs has shown to be more effective in the treatment 
of TMDs. Several studies have shown that patients 
with TMDs have personal characteristics similar to 
those of patients with chronic pain, and because of the 
similar pathophysiology of chronic pain and depression, 
benzodiazepines such as clonazepam has been added to 
the pharmacotherapy of patients with MPDS. Michelotti 
et al assessed the effect of the simultaneous administration 
of fluoxetine and clonazepam on the treatment of 
MPDS. This combination of drugs, irrespective of the 
psychological condition of the patients, resulted in a 90% 
improvement in pain and no side effect was noted after.28 
We also prescribed methocarbamol (muscle relaxant) 
in addition to the above-mentioned medications for 
the patients. This pharmaceutical regimen was highly 
effective for patients and no side effect was reported. It 
is important that the positive effects of treatment do not 
disappear over time. Michelotti et al. used a 780 nm laser 
and showed immediate pain relief after therapy; however, 
the symptoms returned 30 days after treatment.28
In this study, we followed our patients 2 weeks after the 
treatment and the results remained the same. Although a 
period of 2 weeks does not seem to be enough for MPDS 
which has more of a chronic nature, it can be acceptable 
for a preliminary study. Moreover, the major difference of 
our study from the above-mentioned ones is its sample 
size. Had we done the study with a larger sample, we 
might have ended up with a different result. Considering 
the conservative nature of laser and occlusal splint 
therapy, future studies with larger sample groups, longer 
duration of the interventions, and long-term follow-ups 
are needed to determine their efficacy in the management 
of patients with MPDS. The combined effect of other 
available treatment modalities with LLLT and the possible 
synergism or interaction between them should also be 
investigated in future studies.
Conclusion
In this research, a significant improvement was observed 
in pain reduction using both the laser and occlusal splints. 
Therefore, LLLT can be considered as a suitable alternative 
for conventional treatments of MPDS. However, no 
significant improvement was noticed in the maximum 
painless mouth opening or tenderness of the masticatory 
muscles in any of the groups. 
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